Aqua Bio Technology ASA (Oslo Axess: ABT) recently announced its first quarter 2013 financial results. The Company continued its revenue build-up and posted an EBITDA of 3.9 million.
ABT’s revenues were NOK 7.2 million in the first quarter, against NOK 3.4 million in the previous quarter. In the first quarter of 2012 the Company had revenues of NOK 11.9 million, which included sign-on fees for major contracts.
The sales growth is reflected in the NOK 3.9 million EBITDA, which is up from an EBITDA of NOK 0.2 million the previous quarter. The first quarter of 2012 provided EBITDA of NOK 9.6 million.
Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT’s ingredients Aquabeautine XL, Dermaclarine and Beauty Propelline are marine solutions derived from the hatching fluid of salmon, while Oceanx Oil in Serum is based on extract from seaweed.
ABT recently announced its 2012 financial results. The Company had its commercial breakthrough in 2012 and posted revenues of NOK 20.3 million for the year. ABT’s revenues the year before were NOK 0.5 million.
Contracts with two US based customers are the main reason for the commercial success. Aqua Bio Technology’s lead ingredient Aquabeautine XL™ is now included in new skincare products being widely marketed.
Aqua Bio Technology’s EBITDA for 2012 ended at NOK 8.0 million, compared to NOK -8.1 million in 2011. The company’s net result for the year was NOK 0.9 million, against NOK -13.5 the previous year.
For the fourth quarter alone, ABT posted revenues of NOK 3.4 million and an EBITDA of NOK 0.2 million. Net result for the fourth quarter was NOK -2.7 million.
The contracts secure ABT total revenues of more than NOK 120 million in the period 2012-2017, in the form of exclusivity and minimum royalty payments for Aquabeautine XL™. Product sales are expected to provide additional revenues.
Norwegian firm Aqua Bio Technology has reported a fall in revenue in the second quarter of 2012. The company posted a significant sales increase in the first quarter of the year when two major contracts boosted income to NOK11.9m. However, second quarter income was just NOK0.1m, compared with NOK0.4m in the same period of 2011.
The company, which is responsible for Aquabeautine XL, an anti-ageing skin care ingredient derived from the hatching fluid of salmon, reported sales of NOK12.1m in the first half of the year, a considerable increase compared with sales of NOK0.4m in the prior year period.
The company expects the launch of three new products in September will boost income in the second half of 2012. The products will be launched ahead of schedule – the result of accelerated product development in the second quarter. And based on the current order backlog, ABT forecasts significant sales growth in the second half of 2012 and in coming years.
Aqua Bio Technology ASA (Oslo Axess: ABT) today announced a partnership with Amway, one of the world’s largest direct sellers, for the use of ABT’s lead marine-derived ingredient Aquabeautine XL® in ARTISTRY® skincare products. ABT expects the agreement to provide revenues of at least NOK 8 million over the next 30 months, with a significant upside potential.
“The agreement with Amway is our most important commercial milestone to date. It confirms the potential of Aquabeautine XL® as a key component in the next generation of skincare products. Furthermore, our relationship with Amway will serve as an important reference as we roll out our new marketing strategy,” said ABT’s CEO Arvid Lindberg.
Michigan, US-based Amway is a worldwide leader in direct selling, with more than three million Independent Business Owners (IBOs) in more than 80 countries and territories around the world. Its ARTISTRY® is among the world’s top five, largest-selling, premium skincare brands.
Scots and Nordic scientists set to explore sustainable skincare utilizing marine natural ingredientsPosted On: January 30, 2012
Scottish company Aquapharm has joined forces with Norwegian firm Aqua Bio Technology (ABT) to create a new generation of sustainable ingredients for the skincare market.
Together the companies hope to identify natural marine ingredients that could replace the petroleum-based components used extensively within the skincare market.
Scientists at Aquapharm believe marine microbes are the key to finding the bio-active ingredients of the future, and have developed specialist fermentation processes to source and produce such extracts.
Now they will undertake a development program in conjunction with ABT, sharing their expertise in a bid to prove these extracts can be produced with minimal environmental impact – and successfully commercialized for the personal care market.
Presperse Corporation is pleased to announce that they have entered into a distribution agreement with Aqua Bio Technologies ASA (ABT) based in Norway. ABT develops and produces patented ingredients and technologies based on extensive research and development.
Their novel marine active ingredients are derived from the pure and protected environment of Northern waters. ABT’s flagship ingredient, Aquabeautine XL™, is a patented marine solution that adds moistureand improves the renewal of skin cells in an effective and gentle manner. The first self-limiting enzyme of its kind, it is also proven to deliver anti-aging effects in vivo. 100% natural,biodegradable and sustainable, Aquabeautine XL™ is targeted for use in anti-aging products, spa/cosmeceutical products, as well as products for sensitive skin.
Aqua Bio Technology (Oslo Axess : ABT) a Norwegian marine biotech firm developing, producing and selling patented marine based ingredients and technologies to the international cosmetic and skin care industry, today announced it has entered into a sales agreement of with a highly regarded Asian manufacturer of skin care products. As a part of the agreement, ABT will supply its bioactive ingredient Zonase X(TM) to be the key ingredient in a new product line the manufacturer will launch in January 2011.
The new line will consist of five products, developed in collaboration with ABT. The new skin care line will initially be introduced in the Asian markets through the manufacturer’s existing distribution channels. In addition, the manufacturer is also in discussion with distributors in Australia and selected European countries regarding launch in those markets.
Due to competitive reasons, the manufacturer has requested that it is not named until the products are launched. The reason is that the manufacturer considers Zonase X(TM) a novel and highly innovative technology.
Norwegian marine biotechnology company Aqua Bio Technology ASA (ABT) has strengthened its organization, and has secured valuable competence for the company’s further growth and commercial development with the appointment of Arvid Lindberg as the new CEO, and Fanny Fagot-Coste as the Head of sales and Product Development.
Arvid Lindberg (37) takes the role as ABT’s new CEO. He holds a degree in economics from the Norwegian School of Economics and Business Administration in Bergen and comes from the position as Business Unit Director in Roche.
On the sales and product development side, the company has hired Fanny Fagot-Coste (31) as the new Sales Manager Asia /Head of Product Development. Fanny is French and has a double Masters degree in Bioengineering and Cosmetology (Honours) from Universite de Technologie de Compiegne (UTC) and Universite Paris XI, Faculty of Pharmacy.